EUVIMEDEUVIMED entdecken
Crossref

Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis

Julia M Eichhorn, Jasmin Menning, Linda Schäker-Hübner iD, Finn K Hansen iD, Philipp König iD, Gerd Bendas iD

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Julia M Eichhorn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Bonn, An der Immenburg 4, Bonn53121, Germany. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Histone Deacetylases, Piperidines. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA/RNA helicase Schlafen11 (SLFN11) is considered a sensitivity marker of various tumor cells for cytotoxic treatment with DNA damaging agents (DDA), such as cisplatin and PARP inhibitors (PARPi). Cells can epigenetically silence SLFN11 expression to gain chemoresistance, which can be targeted by HDAC inhibitors (HDACi). Here, we investigate the predictive value of SLFN11 expression for the response to three different PARPi in ovarian cancer cells. Furthermore, we target its epigenetic downregulation via HDACi for sensitization to cisplatin and PARPi. We show that HDAC3 plays a key role in SLFN11 silencing in W1 and W1CR ovarian cancer cells, confirmed by an HDAC3 knockdown approach. Therefore, addressing HDAC3 by novel class I HDACi DS-103 and FL-007 at non-toxic concentrations restored SLFN11 expression with various consequences for DDA treatment in W1, W1CR, and SKOV-3 cells. While DS-103 and FL-007 significantly sensitized cisplatin-resistant W1CR cells to cisplatin to the level of W1 cells, the response to various PARPi remains divergent. Whereas both HDACi induced significant sensitization in W1 and W1CR cells, and DS-103 in SKOV-3 cells for niraparib cytotoxicity, cells remain unaffected in response to olaparib and rucaparib. Both compounds were also shown to be less dependent on, or independent of, SLFN11 in different ovarian cancer cells. In sum, the first time reported functional link of HDAC3 and SLFN11 appears an attractive co-treatment opportunity of DDA with HDACi. This is particularly promising for niraparib as it has a broader approval independent of BRCA status compared to other PARPi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinOvarian NeoplasmsHistone DeacetylasesPiperidinesHistone Deacetylase InhibitorsIndazolesNuclear ProteinsAntineoplastic AgentsHumansFemaleHistone Deacetylase 3Cell Line, TumorDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase Inhibitors

Substanzen

CisplatinHistone Deacetylase 3Histone DeacetylasesPiperidinesniraparibHistone Deacetylase InhibitorsIndazolesNuclear ProteinsAntineoplastic AgentsSLFN11 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, University of Bonn, An der Immenburg 4, Bonn53121, Germany.

ORCID-Profile: Linda Schäker-Hübner, Finn K Hansen, Philipp König, Gerd Bendas

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Eichhorn, J. M., Menning, J., Schäker-Hübner, L., Hansen, F. K., König, P., & Bendas, G. (2026). Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00312

Vancouver

Eichhorn JM, Menning J, Schäker-Hübner L, Hansen FK, König P, Bendas G. Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00312

BibTeX
@article{Eichhorn2026,
  author = {Eichhorn, Julia M and Menning, Jasmin and Schäker-Hübner, Linda and Hansen, Finn K and König, Philipp and Bendas, Gerd},
  title = {Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00312}
}
Kostenlos starten →